A Phase 1/2, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Topical Antimicrobial (NEO101) in the Reduction or Eradication of Staphylococcus aureus Nasal Carriage among Adults

Exclusion Criteria1

• Subjects have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug, have clinical evidence of active cutaneous infection, have had skin or soft tissue infection with S. aureus within 30 days prior to randomization, have documented disruption of the nasal or facial bones, have atopic dermatitis/eczema, allergic rhinitis, nasal polyps, or nasal piercings, have a history of hypersensitivity or allergic reaction to parabens, sodium sulfite or any other ingredient in the vehicle formulation.